Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
JAMA ( IF 120.7 ) Pub Date : 2021-10-26 , DOI: 10.1001/jama.2021.15286 Timothy S Anderson 1 , John Z Ayanian 2, 3 , Jeffrey Souza 4 , Bruce E Landon 4
中文翻译：
与患有阿尔茨海默病和轻度认知障碍的医疗保险受益人相比，有资格参加 Aducanumab 治疗阿尔茨海默病临床试验的参与者的代表性。
更新日期：2021-09-09
JAMA ( IF 120.7 ) Pub Date : 2021-10-26 , DOI: 10.1001/jama.2021.15286 Timothy S Anderson 1 , John Z Ayanian 2, 3 , Jeffrey Souza 4 , Bruce E Landon 4
Affiliation
中文翻译：
与患有阿尔茨海默病和轻度认知障碍的医疗保险受益人相比，有资格参加 Aducanumab 治疗阿尔茨海默病临床试验的参与者的代表性。
京公网安备 11010802027423号